Literature DB >> 6801651

Synthetic peptide fragment of src gene product inhibits the src protein kinase and crossreacts immunologically with avian onc kinases and cellular phosphoproteins.

T W Wong, A R Goldberg.   

Abstract

All the known avian sarcoma viruses have associated protein kinase activities that phosphorylate tyrosine residues of their target proteins. A decapeptide fragment of pp60src of Rous sarcoma virus (RSV), residues 415-424, and an analog of that sequence have been chemically synthesized by solid-phase methods. The two decapeptides were not phosphorylated by pp60src of RSV, P90 of Y73 avian sarcoma virus, or P140 of Fujinami sarcoma virus. However, both peptides were able to inhibit competitively the kinase activities associated with the transforming proteins. Antiserum was raised against one of the peptides and IgG was purified from the serum by affinity chromatography. The antibody was able to precipitate pp60src of RSV as well as P90 of Y73 virus from cells infected with these viruses. The antibody also precipitated a number of high molecular weight phosphoproteins from normal chicken and rat fibroblasts and from several lines of virus-transformed cells.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6801651      PMCID: PMC349277          DOI: 10.1073/pnas.78.12.7412

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

Review 1.  The role of cyclic-AMP-dependent protein kinase in the regulation of glycogen metabolism in mammalian skeletal muscle.

Authors:  P Cohen
Journal:  Curr Top Cell Regul       Date:  1978

2.  Evidence that the avian sarcoma virus transforming gene product is a cyclic AMP-independent protein kinase.

Authors:  R L Erikson; M S Collett; E Erikson; A F Purchio
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

3.  Evidence that the src gene product of Rous sarcoma virus is membrane associated.

Authors:  J G Krueger; E Wang; A R Goldberg
Journal:  Virology       Date:  1980-02       Impact factor: 3.616

4.  Structural analysis of the avian sarcoma virus transforming protein: sites of phosphorylation.

Authors:  M S Collett; E Erikson; R L Erikson
Journal:  J Virol       Date:  1979-02       Impact factor: 5.103

5.  Transforming gene product of Rous sarcoma virus phosphorylates tyrosine.

Authors:  T Hunter; B M Sefton
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

6.  The nonstructural components of polyproteins encoded by replication-defective mammalian transforming retroviruses are phosphorylated and have associated protein kinase activity.

Authors:  W J Van de Ven; F H Reynolds; J R Stephenson
Journal:  Virology       Date:  1980-02       Impact factor: 3.616

7.  Characterization of the transforming gene of Fujinami sarcoma virus.

Authors:  T Hanafusa; L H Wang; S M Anderson; R E Karess; W S Hayward; H Hanafusa
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

8.  An activity phosphorylating tyrosine in polyoma T antigen immunoprecipitates.

Authors:  W Eckhart; M A Hutchinson; T Hunter
Journal:  Cell       Date:  1979-12       Impact factor: 41.582

9.  Nucleotide sequence of an avian sarcoma virus oncogene (src) and proposed amino acid sequence for gene product.

Authors:  A P Czernilofsky; A D Levinson; H E Varmus; J M Bishop; E Tischer; H M Goodman
Journal:  Nature       Date:  1980-09-18       Impact factor: 49.962

10.  Fujinami sarcoma virus: an avian RNA tumor virus with a unique transforming gene.

Authors:  W H Lee; K Bister; A Pawson; T Robins; C Moscovici; P H Duesberg
Journal:  Proc Natl Acad Sci U S A       Date:  1980-04       Impact factor: 11.205

View more
  21 in total

Review 1.  Molecular mimicry as a mechanism for virus-induced autoimmunity.

Authors:  R S Fujinami; M B Oldstone
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

2.  Forms of pp60v-src isolated from Rous sarcoma virus-transformed cells.

Authors:  M S Collett; S K Belzer
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

3.  Development and characterization of antisera specific for amino- and carboxy-terminal regions of pp60src.

Authors:  M D Resh; R L Erikson
Journal:  J Virol       Date:  1985-07       Impact factor: 5.103

4.  Epidermal growth factor (EGF) modulation of feline sarcoma virus fms tyrosine kinase activity, internalization, degradation, and transforming potential in an EGF receptor/v-fms chimera.

Authors:  H Riedel
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

Review 5.  Onc genes and other new targets for cancer chemotherapy.

Authors:  H Busch
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

6.  On the nature of crossreactions observed with antibodies directed to defined epitopes.

Authors:  E A Nigg; G Walter; S J Singer
Journal:  Proc Natl Acad Sci U S A       Date:  1982-10       Impact factor: 11.205

7.  Antibodies of predetermined specificity detect two retroviral oncogene products and inhibit their kinase activities.

Authors:  S Sen; R A Houghten; C J Sherr; A Sen
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

8.  Immunofluorescent localization of the transforming protein of Rous sarcoma virus with antibodies against a synthetic src peptide.

Authors:  E A Nigg; B M Sefton; T Hunter; G Walter; S J Singer
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

9.  Anti-peptide antibodies detect oncogene-related proteins in urine.

Authors:  H L Niman; A M Thompson; A Yu; M Markman; J J Willems; K R Herwig; N A Habib; C B Wood; R A Houghten; R A Lerner
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

10.  Use of antibodies directed against synthetic peptides for identifying cDNA clones, establishing reading frames, and deducing the gene order of measles virus.

Authors:  C D Richardson; A Berkovich; S Rozenblatt; W J Bellini
Journal:  J Virol       Date:  1985-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.